Novel mRNA and vector-based covid-19 vaccinations have shown high efficacy in preventing symptomatic COVID-19 infections. Compared with the number of performed vaccinations, rates of severe side effects seem low. Rare prothrombotic coagulation disorders with suspected association to ChAdOx1 nCoV-19 (AstraZeneca) have been reported. These cases have gathered considerable media attention and caused a temporary pause of usage of the AstraZeneca vaccine in Europe and several other countries and are currently discussed as vaccine-induced immune thrombotic thrombocytopenia (VITT). However, hemorrhagic complications from ChAdOx1 nCoV-19 vaccination have also been reported but, so far, received less public attention despite considerable potential for life-threatening complications. Here we present a case of severe immune thrombocytopenia after ChAdOx1 covid-19 vaccination and its successful primary management.
【저자키워드】 Infectious diseases, thrombocytopenia, COVID vaccination, ITP, platelet pathology / inherited, aquired, ITP associated with Covid vaccination, ITP associated with AstraZeneca Covid vaccination, secondary ITP, 【초록키워드】 Efficacy, Vaccine, Europe, vaccination, media, immune, mRNA, symptomatic, management, Complication, complications, novel, ChAdOx1, AstraZeneca, ChAdOx1 nCoV-19, Immune thrombocytopenia, association, Vaccinations, Hemorrhagic, Side effect, COVID-19 infections, thrombotic, life-threatening, country, prothrombotic, coagulation disorder, shown, performed, caused, reported, less, 【제목키워드】 ChAdOx1, report, secondary,